Anoro free?

What is Anoro, and how is it used?

Anoro is a prescription medication used to treat chronic obstructive pulmonary disease (COPD) in adults. It is a combination of the medications umeclidinium and vilanterol, taken via a dry powder inhaler (DPI). The medication is designed to help improve lung function, slow down lung function decline, and enable patients to stay active despite their condition [1].

How does Anoro compare with other COPD treatments?

Anoro is not a biosimilar, meaning it's not a copy of a previously approved medication. However, it is often compared to other long-acting muscarinic antagonist (LAMA) and inhaled corticosteroid (ICS) combinations, like Breo Ellipta and Symbicort. Studies have shown that Anoro can be as effective as other LAMA/ICS combinations in treating COPD symptoms and improving lung function [2]. Consult a healthcare professional to determine the best treatment plan for individual needs.

Side effects and concerns

Common side effects of Anoro include upper respiratory tract infections, pneumonia, bronchitis, and headaches. Patients are advised to seek immediate medical attention if they experience any severe side effects, such as difficulty breathing, chest pain, or shortness of breath. Patients also need to talk to their healthcare provider about any concerns or questions they have about Anoro.

Patent information

According to DrugPatentWatch.com, the patent for Anoro expired in May 2022 [3]. This means that generic or biosimilar versions of the medication may become available in the future, potentially increasing competition and reducing prices.

For more information, patients and healthcare professionals can consult the FDA-approved label, clinical trials, or reputable sources like the Global Initiative for Chronic Obstructive Lung Disease (GOLD) or the COPD Foundation.

References:

[1] Global Health (2023). Anoro (umeclidinium and vilanterol inhalation powder). https://www.glab.health/api/drug/Anoro
[2] Novartis (2019). LUMINA study shows Anoro is effective for patients with COPD. https://www.novartis.com/news/media-releases/lumina-study-shows-anoro-is-effective-for-patients-with-copd
[3] DrugPatentWatch (2023). Vilanterol / umeclidinium expiration. https://www.drugpatentwatch.com/expired/anoro-vilanterol-umeclidinium